13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05349474
(ClinicalTrials.gov)
April 26, 202221/4/2022Metformin Treatment in Progressive Multiple SclerosisA Double-blind, Placebo Controlled Trial of Metformin Treatment in Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis;Primary Progressive Multiple SclerosisDrug: Metformin 500 Mg Oral Tablet, up to 4 tablets a day;Drug: Placebo oral tablet identical to metformin, up to 4 tablets a dayUniversity of California, Los AngelesNULLRecruiting30 Years65 YearsAll44Early Phase 1United States
2NCT05131828
(ClinicalTrials.gov)
March 8, 202212/11/2021CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying TherapyCCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying TherapyMultiple SclerosisDrug: Metformin and clemastine in combination;Drug: PlaceboCambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecruiting25 Years50 YearsAll50Phase 2United Kingdom
3NCT05298670
(ClinicalTrials.gov)
February 1, 202217/3/2022Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis PatientsDrug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis PatientsMultiple SclerosisDrug: MetFORMIN 1000 Mg Oral Tablet;Drug: Interferon beta-1aGerman University in CairoNULLRecruiting18 Years50 YearsAll80Phase 2Egypt
4NCT04121468
(ClinicalTrials.gov)
February 24, 20202/10/2019A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple SclerosisA Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children With Multiple SclerosisMultiple Sclerosis (MS)Drug: Metformin;Other: PlaceboThe Hospital for Sick ChildrenQueen's University;Ontario Institute for Regenerative Medicine;Unity Health Toronto;Stem Cell Network;Multiple Sclerosis Society of CanadaRecruiting10 Years25 YearsAll30Phase 1/Phase 2Canada